Unicycive Therapeutics UNCY 深 沪
等待开盘 05-19 09:30:00 美东时间
8.15
-0.110
-1.33%
华盛通- 最 高8.40
- 今 开8.26
- 成交量 48.80万股
- 最 低 7.96
- 昨 收 8.26
- 总市值 2.18亿
- 52周最高 11.00
- 市盈率 静 --
- 换手率 1.83%
- 52周最低 3.71
- 委 比 95.40%
- 总股本 2670.00万
- 历史最高 87.30
- 量 比 0.84
- 振 幅 5.33%
- 历史最低 2.02
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $40 to $37.
05-13 21:49
Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 8 percent decrease over losses of $(0.50) per share
05-12 19:48
Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million
Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million Unicycive Therapeutics posted a net loss of USD 12.8 million, swinging from net income of USD 570,000 a year earlier. Operating loss widened 6% to USD 8.44 million as operating expenses climbed 6% to
05-12 18:32
美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元
今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元
04-07 11:53
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $46 to $40.
04-02 21:51
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics April 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Doordash, Phillips 66 and United Therapeutics, on Thursday. HIGHLIGHTS * Doordash DASH.O : JP Morga
04-02 15:21
Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $0.03 by 2511.76 percent. This is a 68.46 percent increase over losses of $(2.60) per
03-30 19:53
Unicycive FY25 net loss narrows 28% to USD 27 million
Unicycive FY25 net loss narrows 28% to USD 27 million Unicycive posted a net loss of USD 27 million for fiscal 2025, narrowing 28%. Operating loss improved to USD 30 million as total operating expenses fell 8% to USD 30 million. Research and development costs dropped 54% to USD 9.1 million, while ge
03-30 18:33
